Clinical characteristics of patients with panel-consensus diagnosed large cell neuroendocrine carcinoma
| Total cohort | Chemotherapy clusters | p-value | ||||
| NSCLC-t | NSCLC-pt | SCLC-t | NSCLC-t versus NSCLC-pt | NSCLC-t versus SCLC-t | ||
| Patients | 128 (100) | 60 (46) | 20 (16) | 48 (38) | ||
| Age years | 65 (56–71) | 64 (56–69) | 70 (57–74) | 63 (55–70) | 0.24# | 0.88# |
| Male | 75 (59) | 33 (55) | 12 (60) | 30 (63) | 0.70 | 0.43 |
| Number of organs with metastases | 0.67¶,+ | 0.012¶,+ | ||||
| 1 | 61 (48) | 29 (48) | 14 (70) | 18 (38) | ||
| 2 | 44 (34) | 24 (40) | 5 (25) | 15 (31) | ||
| 3 | 11 (9) | 2 (3) | 0 (0) | 9 (19) | ||
| >3 | 12 (9) | 5 (8) | 1 (5) | 6 (13) | ||
| Organ metastases at diagnosis | ||||||
| Bone | 34 (27) | 14 (23) | 5 (25) | 15 (31) | 0.88 | 0.34 |
| Liver | 68 (53) | 30 (50) | 10 (50) | 28 (58) | 1.00 | 0.39 |
| Brain | 17 (13) | 7 (12) | 2 (10) | 8 (17) | 0.57 | 0.81 |
| Adrenal gland | 21 (16) | 9 (15) | 2 (10) | 10 (21) | 0.57 | 0.43 |
| Lung | 16 (13) | 10 (17) | 2 (10) | 4 (8) | 0.47 | 0.20 |
| Pleura | 2 (2) | 1 (2) | 0 (0) | 1 (2) | 1.00+ | 1.00+ |
| Lymph node | 28 (22) | 14 (23) | 4 (20) | 10 (21) | 0.76 | 0.76 |
| Nonclustered subtype of chemotherapy | ||||||
| Gemcitabine | 46 (36) | 46 (76) | ||||
| Paclitaxel | 7 (5) | 7 (12) | ||||
| Docetaxel | 6 (5) | 6 (10) | ||||
| Vinorelbine | 1 (1) | 1 (2) | ||||
| Etoposide | 48 (38) | 48 (100) | ||||
| Pemetrexed | 20 (16) | 20 (100) | ||||
| Cycles of chemotherapy | 0.30§ | 0.09§ | ||||
| 1 | 18 (14) | 6 (10) | 2 (10) | 10 (21) | ||
| 2 | 15 (12) | 5 (8) | 4 (20) | 6 (13) | ||
| 3 | 14 (11) | 6 (10) | 3 (15) | 5 (10) | ||
| 4 | 63 (49) | 30 (50) | 11 (55) | 22 (46) | ||
| >4 | 16 (13) | 11 (18) | 0 (0) | 5 (10) | ||
| Data missing | 2 (2) | 2 (3) | 0 (0) | 0 (0) | ||
| Additional chemotherapy | ||||||
| Second-line | 29 (23) | 13 (22) | 4 (20) | 12 (25) | 0.88 | 0.68 |
| Third-line | 6 (5) | 3 (5) | 1 (5) | 2 (4) | 1.00+ | 1.00+ |
Data are presented as n (%) or median (interquartile range), unless otherwise stated. Bold type represents statistical significance. NSCLC: nonsmall cell lung carcinoma; NSCLC-t: NSCLC cluster of gemcitabine, paclitaxel, docetaxel and vinorelbine chemotherapy; NSCLC-pt: NSCLC cluster of pemetrexed chemotherapy; SCLC-t: small cell lung carcinoma cluster of etoposide chemotherapy. #: Mann–Whitney U-test; ¶: compared ≤2 organ metastases with >2 organ metastases; +: Fisher exact test; §: compared ≤2 cycles versus ≥3 cycles of chemotherapy, excluding unknown cases.